Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Capricor Therapeutics, Inc. CAPR

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
▼ 100.0% YoY
$-105.0M
$-72.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -105.0
10M20M-50M-100M
2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -191.1% · Net -181.7%
-5000%
200720162025
ROE
FY2025 · ROE -46.6%
-50%-100%-150%
200720162025
Three returns, three denominators.

Each USD of equity lost 47 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -72.7
-30M-60M
200720162025
Net buybacks $M Dividends $M
FY2020 · Dividends · · Net buybacks -27.3
-10M-20M
201820192020

Total assetsUSD 355.9M
EquityUSD 305.8M
CashUSD 287.8M
Current ratio9.01×

Equity funds 86% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CAPR, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0◌◌◌◌
Operating income $B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
EBITDA $B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.00.0◌◌◌◌◌◌◌◌◌◌◌0.0◌◌◌◌◌
Net income $B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0◌◌◌
EPS, diluted $−2.26−1.15−0.83−1.18−0.87−0.88−2.06−5.170.09−1.01−0.81−0.53−0.85−0.21−0.13−0.19◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %−46.6−48.2−129.6−134.5−67.2−78.0−133.4−191.8—————−63.2−66.7−78.2−25.6−113.1−113.4
Shares out B0.060.050.030.030.020.020.010.030.030.020.020.010.010.040.040.03◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image